Answers are grounded in this paper and cite their sources.
In this single-center case series involving young patients with relapsed or refractory cancer, incorporation of integrative clinical sequencing data into clinical management was feasible, revealed potentially actionable findings in 46% of patients, and was associated with change in treatment and family genetic counseling for a small proportion of patients. The lack of a control group limited assessing whether better clinical outcomes resulted from this approach than outcomes that would have occurred with standard care.
No takes yet. Share an insight, caveat, or question.
Mody et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: